Phased affinity-controlled delivery of vascular endothelial growth factor, fibroblast growth factor-2, and platelet derived growth factor enhances in vitro angiogenesis

Abstract

Angiogenesis, the growth of vasculature from existing blood vessels, requires the coordinated secretion of multiple angiogenic growth factors that each stimulate the cellular recruitment, patterning, and morphogenesis inherent to vascular network formation. Among these secreted factors, vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), and platelet derived growth factor (PDGF) amplify key stages of angiogenesis. Disruptions in their secretion have been implicated in poor vascular network formation. Current methods for exploring variations in the phased presentation of multiple different proteins are limited, which has restricted our ability to explore the effect of growth factor timing on angiogenesis. To address this knowledge gap, we developed affibodies, which are alpha-helical binding proteins, to phase the release of VEGF-165, FGF-2, and PDGF-BB from a single delivery vehicle via specific protein-affibody affinity interactions. We used yeast surface display to engineer three VEGF-, three FGF-2-, and two PDGF-specific affibodies with a wide range of affinities for their target proteins spanning dissociation constants of 3.08 {+/-} 0.21 nM to 4550 {+/-} 590 nM. We demonstrated that the cumulative release of VEGF and FGF-2 is inversely correlated with the strength of the protein-affibody affinity interaction and that hydrogels containing multiple protein-specific affibodies can control the release of VEGF, FGF-2, and PDGF, largely in accordance with the strength of the affinity interactions. Using a rat-derived intact microvascular fragment model of in vitro angiogenesis, we revealed that sequential delivery of soluble VEGF, followed by FGF-2, and then PDGF enhances vascular network length by 2.8-fold and branching by 4.1-fold compared to untreated MVFs. We then designed an affibody-conjugated polyethylene glycol maleimide (PEG-MAL) hydrogel to mimic this sequence of protein delivery, resulting in a 3.0-fold increase in vascular network length and a 2.3-fold increase in vascular branching compared to all other hydrogel compositions and the sequential delivery of soluble growth factors. Changing temporal growth factor presentation with affibody-conjugated hydrogels altered the expression of key angiogenic genes involved in vessel stabilization and destabilization and matrix remodeling. Perivascular coverage measured by the colocalization of lectin and alpha smooth muscle actin staining was similar between all treatment groups, suggesting pericyte recruitment to stabilize expanded vascular networks created by the soluble and affibody-mediated delivery of the optimal sequence of proteins. Overall, this work establishes a new biomaterial platform for modulating the timing of growth factor delivery, enabling the exploration of how temporal variations in protein secretion impact regeneration and development. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=127 SRC="FIGDIR/small/662647v2_ufig1.gif" ALT="Figure 1"> View larger version (41K): org.highwire.dtl.DTLVardef@471657org.highwire.dtl.DTLVardef@10bc491org.highwire.dtl.DTLVardef@1961f9dorg.highwire.dtl.DTLVardef@f5b8ba_HPS_FORMAT_FIGEXP M_FIG C_FIG